Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
CryoPortFRA:CKX -1.54%69 3-Year EBITDA Growth Rate is 30.70% as of Jun. 2026, which is 31% above its 10-year median of 23.35. GuruFocus rates FRA:CKX with a GF Score™ of 69/100 and a GF Value™ of €8.69 (Significantly Overvalued). The stock has 7 warning signs investors should review. Among 874 Transportation companies, CryoPort ranks better than 85.58% on this metric.
During the past 12 months, CryoPort's average EBITDA Per Share Growth Rate was -246.50% per year.
During the past 3 years, the average EBITDA Per Share Growth Rate was 30.70% per year.
During the past 5 years, the average EBITDA Per Share Growth Rate was 34.00% per year.
During the past 10 years, the average EBITDA Per Share Growth Rate was 9.30% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 13 years, the highest 3-Year average EBITDA Per Share Growth Rate of CryoPort was 58.60% per year. The lowest was -160.90% per year. And the median was 23.35% per year.
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
CryoPort 3-Year EBITDA Growth Rate Related Terms
FRA:CKX vs FWRD, RLGT, PAL: 3-Year EBITDA Growth Rate Comparison
For the Integrated Freight & Logistics subindustry, CryoPort's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
CryoPort 3-Year EBITDA Growth Rate vs Transportation Industry
For the Transportation industry and Industrials sector, CryoPort's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where CryoPort's 3-Year EBITDA Growth Rate falls into.
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of 30.70% mean?
CryoPort (FRA:CKX) has a 3-Year EBITDA Growth Rate of 30.70% as of Jun. 2026. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for CryoPort and its competitors. This is 31% above median its historical median of 23.35. According to the industry distribution chart, CryoPort ranks #126 out of 874 companies in the Transportation industry, placing it in the top 14.4%.
Is CryoPort's 3-Year EBITDA Growth Rate too high?
CryoPort's current 3-Year EBITDA Growth Rate of 30.70% is 31% above median its 10-year median of 23.35. The Transportation industry median 3-Year EBITDA Growth Rate is 5.00. CryoPort's value of 30.70% is 514% above this industry median. Based on the distribution chart, CryoPort ranks #126 out of 874 companies in the Transportation industry, which is in the top quartile — a strong position relative to peers. Overall, CryoPort has a GF Score™ of 69/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does CryoPort's 3-Year EBITDA Growth Rate compare to FWRD and RLGT?
According to the Transportation industry distribution chart, CryoPort ranks #126 out of 874 companies for 3-Year EBITDA Growth Rate. This places CryoPort in the top 14% of its industry — outperforming the majority of peers. The industry median 3-Year EBITDA Growth Rate is 5.00. CryoPort's value of 30.70% is 514% above this benchmark. While the company's 10-year median is 23.35 vs. the industry median of 5.00, CryoPort has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Transportation company?
The median 3-Year EBITDA Growth Rate among Transportation companies is 5.00, based on 874 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. CryoPort's current 3-Year EBITDA Growth Rate of 30.70% is 514% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for CryoPort and its competitors. For the Transportation industry, the median 3-Year EBITDA Growth Rate is 5.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. CryoPort's current 3-Year EBITDA Growth Rate is 30.70%, which is 31% above median its own 10-year median of 23.35. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CryoPort stock overvalued right now?
Based on GuruFocus' analysis, CryoPort (FRA:CKX) is currently considered Significantly Overvalued. The stock's GF Value™ is €8.69, compared to a current price of €13.70 — trading 57.7% above its estimated fair value. The current 3-Year EBITDA Growth Rate is 30.70%, which is 31% above median its 10-year median of 23.35 and 514% above the Transportation industry median of 5.00. CryoPort's overall GF Score™ is 69/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For CryoPort (FRA:CKX), the current 3-Year EBITDA Growth Rate is 30.70% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is CryoPort (FRA:CKX) Overvalued in 2026?
Based on GuruFocus' analysis, CryoPort stock appears to be overvalued.
The current stock price of €13.70 is trading 57.7% above its estimated GF Value™ of €8.69.
GuruFocus considers CryoPort to be Significantly Overvalued.
Key valuation signals for FRA:CKX:
3-Year EBITDA Growth Rate: 30.70% (31% above median its 10-year median of 23.35)
GF Value™: €8.69 vs. price of €13.70 (57.7% above fair value)
Industry Position: 514% above the Transportation median (#126 of 874)
No single metric tells the full story. See the FRA:CKX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
CryoPort Inc is a provider of integrated, temperature-controlled supply chain solutions for the life sciences industry, with a focus on supporting the cell and gene therapy market. The company provides services such as temperature-controlled logistics, biostorage, bioservices, cryopreservation solutions, and cryogenic systems manufacturing. It operates through two reportable segments: Life Sciences Services and Life Sciences Products. It generates the majority of its revenue from the Life Sciences Services segment.
69GF Score
Get the complete analysis for FRA:CKX
3-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:CKX has been successfully added to your 
